Skip to main content
Marker Therapeutics, Inc. logo

Marker Therapeutics, Inc. — Investor Relations & Filings

Ticker · MRKR ISIN · US57055L1070 US Manufacturing
Open in API
Filings indexed 899 across all filing types
Latest filing 2012-04-16 Annual Report
Country US United States of America
Listing US MRKR

About Marker Therapeutics, Inc.

https://markertherapeutics.com/

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing next-generation T cell-based immunotherapies for hematologic malignancies and solid tumors. The company's core technology is its Multi-Antigen Recognizing (MAR) T cell platform, which utilizes natural, non-genetically modified T cells to recognize and kill heterogeneous tumors. This approach is designed to provide durable anti-tumor responses with a favorable safety profile. Its lead product candidate, MT-601, recognizes six tumor-specific antigens and is being evaluated in a Phase 1 study for patients with lymphoma who have relapsed or are ineligible for anti-CD19 CAR-T cell therapy. The technology was originally developed at Baylor College of Medicine.

Recent filings

Filing Released Lang Actions
Annual Report 2011
Annual Report FY 2011
2012-04-16 English
Regulatory Filings 2012
Regulatory Filings Classification · 100% confidence The document is a Form 12B-25, which is a Notification of Late Filing for an Annual Report on Form 10-K. It states that the 10-K for the period ended December 31, 2011 has not been completed due to administrative delays and will be filed soon. The document does not contain the actual 10-K report or financial data, but is merely a notification of delay in filing. According to the rules, such a notification is classified as a Regulatory Filing (RNS) because it is a compliance document and not the report itself.
2012-03-30 English
SC 13G/A
Major Shareholding Notification
2012-02-14 English
Capital/Financing Update 2011
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated November 23, 2011. It details the entry into a material definitive agreement involving the issuance of securities (units consisting of common stock and warrants), the unregistered sale of equity securities under exemptions, and related information. The content focuses on financing activities, specifically a securities placement and related agreements. The document length is 3646 characters, which is relatively short but contains substantive information about capital raising and securities issuance, not merely an announcement or a certification. Therefore, it fits best under the category for Capital/Financing Update (CAP).
2011-11-23 English
Interim / Quarterly Report 2011
Interim / Quarterly Report 9M 2011
2011-11-21 English
FORM NT 10-Q
Regulatory Filings Classification · 100% confidence The document is a Form 12B-25, which is a Notification of Late Filing submitted to the SEC. It specifically states that the company, TapImmune Inc., has not completed its Quarterly Report on Form 10-Q for the period ended September 30, 2011, due to administrative and accountant delays. The document does not contain the actual financial data or the quarterly report itself but is a notification explaining the delay in filing the Form 10-Q. The document length is only 3086 characters, which is short and consistent with a notification rather than a full report. According to the rules, such a notification is classified as a Regulatory Filing (RNS) because it is a compliance document related to filing deadlines and does not contain substantive financial data or the report itself.
2011-11-14 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.